Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB754 - Provider product page
- Provider
- R&D Systems
- Product name
- Canine IL-4 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects canine IL-4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) IL-4, recombinant mouse IL-4, recombinant rat IL-4, recombinant porcine IL-4, recombinant feline IL-4, or rhIL-13 is observed.
- Reactivity
- Canine
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
O77762
- Isotype
- IgG
- Antibody clone number
- 140429
- Vial size
- 500 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Expression of Toll-like receptors 2 and 9 in cells of dog jejunum and colon naturally infected with Leishmania infantum.
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Figueiredo MM, Amorim IF, Pinto AJ, Barbosa VS, Pinheiro Lde J, Deoti B, Faria AM, Tafuri WL
BMC immunology 2013 May 14;14:22
BMC immunology 2013 May 14;14:22
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G
Vaccine 2007 May 22;25(21):4223-34
Vaccine 2007 May 22;25(21):4223-34
Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL, Holzmuller P, Cavaleyra M, Gonçalves RB, Hottin G, Papierok G
Vaccine 2005 Apr 22;23(22):2825-40
Vaccine 2005 Apr 22;23(22):2825-40
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by IL-4 and Neutralization by Canine IL-4 Antibody. Recombinant Canine IL-4 (Catalog # 754-CL) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Canine IL-4 (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Canine IL-4 Monoclonal Antibody (Catalog # MAB754). The ND50 is typically 0.4-2.0 µg/mL.